Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 21Recruiting 14Active not recruiting 8Unknown 4Terminated 4No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Transitional Cell 9Small Cell Lung Carcinoma 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Melanoma 6Colorectal Neoplasms 6Lung Neoplasms 5Recurrence 4Neoplasms 4Urinary Bladder Neoplasms 3Lymphoma, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Urologic Neoplasms 1Urologic Diseases 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Neoplasms × atezolizumab × Clear all
NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
33 enrolled
Tumor-Agnostic

Neoplasms

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Sanofi

Phase 1/2 Terminated
107 enrolled 30 charts
Tumor-Agnostic

Neoplasms

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT02543645 2018-04-30

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Celldex Therapeutics

Phase 1 Terminated
18 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Clear-cell metastatic renal cell carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡